Latest news with #VertexPharmaceuticalsInc
Yahoo
06-08-2025
- Business
- Yahoo
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial
We recently published . Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an experimental pain medicine. The company dropped as low as 21 percent to $373.2 before a slight uptick to close the day just down by 20.6 percent at $374.98 apiece. In a statement, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said that its clinical trial for VX-993 for the Treatment of Acute Pain 'did not result in a statistically significant improvement' to the enrolled patients. 'Based on these results, Vertex will not progress VX-993 into pivotal development as monotherapy in acute pain,' it said. The termination overshadowed the company's impressive earnings performance in the second quarter and first half of the year. During the quarter, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) swung to a net income of $1.03 billion from a $3.593 billion net loss in the same period last year. Total revenues grew by 12 percent to $2.96 billion from $2.64 billion year-on-year. In the first half, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) swung to a net profit of $1.68 billion from a $2.49 billion net loss year-on-year, while total revenues grew by 8 percent to $5.73 billion from $5.3 billion. While we acknowledge the potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Bloomberg
05-05-2025
- Business
- Bloomberg
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug
Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to displace opioids. The company disclosed the prescription tally in its earnings release Monday. It includes both hospital and retail settings from when the drug, Journavx, became available in early March through April 18. Vertex said revenue from the medicine was 'insignificant' in the first quarter.
Bloomberg
06-03-2025
- Business
- Bloomberg
Vertex's Non-Opioid Pain Drug Gets Some UnitedHealth Coverage
Vertex Pharmaceuticals Inc. 's new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc. 's approved drug lists. The medication, called Journavx, was approved in the US in January. The financial success of new drugs largely depends on how they're treated by pharmacy benefit managers that determine coverage for patients.
Bloomberg
30-01-2025
- Business
- Bloomberg
New Pain Drug Gets FDA Nod as Safer Alternative to Addictive Opioids
Medication is first new type of painkiller in over two decades Analysts have questioned the drug's commercial potential By Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths. Vertex's pill, called Journavx, gained Food and Drug Administration clearance to treat moderate-to-severe acute pain, according to a statement Thursday. Vertex shares rose 0.4% after US markets closed.
